Table 1.

Demographic and baseline characteristics

Characteristic	Treatment-naïve (n = 19)	Relapsed/refractory (n = 26)
Median age (range), y	61 (42–75)	63 (42–76)
Male sex, n (%)	11 (58)	21 (81)
ECOG PS ≤1, n (%)	19 (100)	26 (100)
Bulky disease ≥5 cm, n (%)	10 (53)	13 (50)
Rai stage III–IV, n (%)	10 (53)	7 (27)
CLL-IPI score, n (%)
0–3 (Low/intermediate risk)	7 (37)	11 (42)
4–6 (High risk)	4 (21)	6 (23)
7–10 (Very high risk)	4 (21)	3 (12)
β2-microglobulin >3 mg/L, n (%)	13 (68)	17 (65)
No. prior therapies, median (range)	0	1 (1–9)
Histology, n (%)
CLL	18 (95)	26 (100)
SLL	1 (5)	0
Genomic status, n/n (%)
Del(17)(p13.1)	4/18 (22)	5/25 (20)
Del(11)(q22.3) without or missing del(17)(p13.1)	5/18 (28)	9/26 (35)
Unmutated IGHV	9/17 (53)	17/26 (65)
TP53 mutation	5/18 (28)	6/24 (25)
TP53 mutation + del(17)(p13.1)	4/19 (21)	3/26 (12)

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; IGHV, immunoglobulin heavy-chain variable region gene; IPI, International Prognostic Index; SLL, small lymphocytic lymphoma.